These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
173 related articles for article (PubMed ID: 31273630)
1. Altered Expression of CD44, SIRT1, CXCR4, miR-21, miR-34a, and miR-451 Genes in MKN-45 Cell Line After Docetaxel Treatment. Motamedi M; Razmkhah F; Rezakhani L; Ghasemi S J Gastrointest Cancer; 2020 Jun; 51(2):520-526. PubMed ID: 31273630 [TBL] [Abstract][Full Text] [Related]
2. Frequency of CD44 positive cells in MKN45 cell line after treatment with docetaxel in two and three-dimensional cell cultures. Alizadeh A; Rezakhani L; Anjom Shoa M; Ghasemi S Tissue Cell; 2020 Apr; 63():101324. PubMed ID: 32223952 [TBL] [Abstract][Full Text] [Related]
3. Typhae pollen polysaccharides protect hypoxia-induced PC12 cell injury via regulation of miR-34a/SIRT1. Wang S; Tang Q; Ge F; Guo Q Int J Immunopathol Pharmacol; 2020; 34():2058738420910005. PubMed ID: 32635836 [TBL] [Abstract][Full Text] [Related]
4. Upregulated microRNA-193a-3p is responsible for cisplatin resistance in CD44(+) gastric cancer cells. Lee SD; Yu D; Lee DY; Shin HS; Jo JH; Lee YC Cancer Sci; 2019 Feb; 110(2):662-673. PubMed ID: 30485589 [TBL] [Abstract][Full Text] [Related]
6. Hsa-miR-34a-5p reverses multidrug resistance in gastric cancer cells by targeting the 3'-UTR of SIRT1 and inhibiting its expression. Deng XJ; Zheng HL; Ke XQ; Deng M; Ma ZZ; Zhu Y; Cui YY Cell Signal; 2021 Aug; 84():110016. PubMed ID: 33894312 [TBL] [Abstract][Full Text] [Related]
7. Dysregulation of the miR-34a-SIRT1 axis inhibits breast cancer stemness. Ma W; Xiao GG; Mao J; Lu Y; Song B; Wang L; Fan S; Fan P; Hou Z; Li J; Yu X; Wang B; Wang H; Wang H; Xu F; Li Y; Liu Q; Li L Oncotarget; 2015 Apr; 6(12):10432-44. PubMed ID: 25826085 [TBL] [Abstract][Full Text] [Related]
8. DHA Abolishes the Detrimental Effect of Docetaxel on Downregulation of the MICA via Decreasing the Expression Level of MicroRNA-20a in Gastric Cancer. Shekari N; Javadian M; Ghaffari S; Baradaran B; Darabi M; Kazemi T J Gastrointest Cancer; 2020 Jun; 51(2):545-551. PubMed ID: 31368060 [TBL] [Abstract][Full Text] [Related]
9. MicroRNA-145 exerts tumor-suppressive and chemo-resistance lowering effects by targeting CD44 in gastric cancer. Zeng JF; Ma XQ; Wang LP; Wang W World J Gastroenterol; 2017 Apr; 23(13):2337-2345. PubMed ID: 28428713 [TBL] [Abstract][Full Text] [Related]
10. Let-7a Could Serve as A Biomarker for Chemo-Responsiveness to Docetaxel in Gastric Cancer. Shekari N; Asghari F; Haghnavaz N; Shanehbandi D; Khaze V; Baradaran B; Kazemi T Anticancer Agents Med Chem; 2019; 19(3):304-309. PubMed ID: 30543177 [TBL] [Abstract][Full Text] [Related]
11. Replication Study: The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Yan X; Tang B; Chen B; Shan Y; Yang H; Elife; 2019 Mar; 8():. PubMed ID: 30860027 [TBL] [Abstract][Full Text] [Related]
12. Inhibition of miR-34a reduces cellular senescence in human adipose tissue-derived mesenchymal stem cells through the activation of SIRT1. Mokhberian N; Bolandi Z; Eftekhary M; Hashemi SM; Jajarmi V; Sharifi K; Ghanbarian H Life Sci; 2020 Sep; 257():118055. PubMed ID: 32634429 [TBL] [Abstract][Full Text] [Related]
13. MiR-876-3p regulates cisplatin resistance and stem cell-like properties of gastric cancer cells by targeting TMED3. Peng C; Huang K; Liu G; Li Y; Yu C J Gastroenterol Hepatol; 2019 Oct; 34(10):1711-1719. PubMed ID: 30843262 [TBL] [Abstract][Full Text] [Related]
14. Expression of microRNA-328 Functions as a Biomarker for Recurrence of Early Gastric Cancer (EGC) After Endoscopic Submucosal Dissection (ESD) by Modulating CD44. Xue HG; Yang AH; Sun XG; Lu YY; Tian ZB Med Sci Monit; 2016 Dec; 22():4779-4785. PubMed ID: 27923017 [TBL] [Abstract][Full Text] [Related]
15. MiR-199a-5p represses the stemness of cutaneous squamous cell carcinoma stem cells by targeting Sirt1 and CD44ICD cleavage signaling. Lu RH; Xiao ZQ; Zhou JD; Yin CQ; Chen ZZ; Tang FJ; Wang SH Cell Cycle; 2020 Jan; 19(1):1-14. PubMed ID: 31809227 [TBL] [Abstract][Full Text] [Related]
16. MiR-34a inhibits proliferation and migration of breast cancer through down-regulation of Bcl-2 and SIRT1. Li L; Yuan L; Luo J; Gao J; Guo J; Xie X Clin Exp Med; 2013 May; 13(2):109-17. PubMed ID: 22623155 [TBL] [Abstract][Full Text] [Related]
17. Nanovesicle-mediated systemic delivery of microRNA-34a for CD44 overexpressing gastric cancer stem cell therapy. Jang E; Kim E; Son HY; Lim EK; Lee H; Choi Y; Park K; Han S; Suh JS; Huh YM; Haam S Biomaterials; 2016 Oct; 105():12-24. PubMed ID: 27497057 [TBL] [Abstract][Full Text] [Related]
18. Targeted delivery of miR-200c/DOC to inhibit cancer stem cells and cancer cells by the gelatinases-stimuli nanoparticles. Liu Q; Li RT; Qian HQ; Wei J; Xie L; Shen J; Yang M; Qian XP; Yu LX; Jiang XQ; Liu BR Biomaterials; 2013 Sep; 34(29):7191-203. PubMed ID: 23806972 [TBL] [Abstract][Full Text] [Related]
19. The UCA1/miR-204/Sirt1 axis modulates docetaxel sensitivity of prostate cancer cells. Wang X; Yang B; Ma B Cancer Chemother Pharmacol; 2016 Nov; 78(5):1025-1031. PubMed ID: 27686228 [TBL] [Abstract][Full Text] [Related]
20. Dysregulation of microRNA-34a expression causes drug-resistance to 5-FU in human colon cancer DLD-1 cells. Akao Y; Noguchi S; Iio A; Kojima K; Takagi T; Naoe T Cancer Lett; 2011 Jan; 300(2):197-204. PubMed ID: 21067862 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]